independence solutions occupational therapy, pLLC

141 n. ohioville rd.
new paltz, new york 12561

NYS Entity Status
ACTIVE

NYS Filing Date
MARCH 04, 2013

NYS DOS ID#
4368131

County
ULSTER

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL SERVICE LIMITED LIABILITY COMPANY

Name History
2013 - INDEPENDENCE SOLUTIONS OCCUPATIONAL THERAPY, PLLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • Hiring a shrink could make your company more successful
    By Moneyish - Monday Sep 4, 2017

    This isn’t the kind of occupational therapy you’re used to. When Jonathan Pellegrin, the former chairman and CEO of publishing company Johnson Hill Press and author of “The Art of Selling the Family Business,” saw trouble brewing at his company, he knew just where to turn: a therapist specializing in workplace issues. With a history...

    Source: New York Post: Business
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • DotCom Therapy Gets Shot at Silicon Valley VCs After Pitch Contest
    By Jeff Buchanan - Tuesday Aug 22, 2017

    DotCom Therapy, a Madison, WI-based startup that has developed software allowing the dozens of therapists it employs to provide remote speech therapy services to schoolchildren, captured first place in one of Wisconsin’s more closely watched pitch competitions on Monday. The contest DotCom Therapy won was the fourth annual “Pressure Chamber,” which is put on by […]

    Source: Xconomy VC, Deals, & Startups Feed
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • First genetic engineering therapy approved by the FDA for leukemia
    By Beth Mole - Wednesday Aug 30, 2017

    Safety risks still an issue for the CAR-T therapy, but new hope for young patients.

    Source: Ars Technica
independence solutions occupational therapy pllc new paltz ny